Atezolizumab - StatPearls - NCBI Bookshelf
2024年10月29日 · Atezolizumab is a humanized IgG1 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1). Atezolizumab has received FDA approval for multiple …
TECENTRIQ ® (atezolizumab) proposed mechanism of action
Find information on how TECENTRIQ® (atezolizumab) targets the ligand PD-L1 to potentially restore antitumor T-Cell activity for the treatment of metastatic non-small cell lung cancer …
Atezolizumab: Uses, Interactions, Mechanism of Action
Atezolizumab is a monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
Atezolizumab - Wikipedia
Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell …
TECENTRIQ® (atezolizumab) HCP | Efficacy, Safety, PI & MOA
TECENTRIQ, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II-IIIA non-small cell lung cancer …
Clinical Review - Atezolizumab (Tecentriq) - NCBI Bookshelf
Atezolizumab (Tecentriq) is an engineered humanized immunoglobulin monoclonal antibody targeting PD-L1 and provides a dual blockade of interactions between PD-L1 and its receptors …
Atezolizumab: Dosage, Mechanism/Onset of Action, Half-Life
2020年2月10日 · Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that binds to programmed death ligand 1 (PD-L1) to selectively prevent the interaction …
Atezolizumab - PubChem
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is …
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 …
2017年7月17日 · Here, we report the crystal structures of PD-L1 in complex with atezolizumab and durvalumab to elucidate the precise epitopes involved and the structural basis for PD …
Oncology Overview: Atezolizumab (Tecentriq) - Pharmacy Times
2021年12月14日 · Atezolizumab (Tecentriq) is a monoclonal antibody indicated for treatment as a single or in-combination agent in 6 types of carcinomas in pediatric and adult populations.